No other company goes further when it comes to testing their products. Canabidol™ customers can access the exact lab report for the item they have purchased by searching our database of analytical results. With over a thousand reports available and more being added daily. We go above and beyond when it come to providing you with the confidence in buying our product time and time again.
Over the past few years, increasing public and political pressure has supported legalization of medical marijuana. One of the main thrusts in this effort has related to the treatment of refractory epilepsy—especially in children with Dravet syndrome—using cannabidiol (CBD). Despite initiatives in numerous states to at least legalize possession of CBD oil for treating epilepsy, little published evidence is available to prove or disprove the efficacy and safety of CBD in patients with epilepsy. This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy, and highlights issues related to the use of currently available CBD products.
Author Gerhard Nahler found it most surprising that an entire group of authors were “tempted to over-interpret results.” However, he felt that misinterpretations are not entirely uncommon, stating “People overlook quite frequently that “in vitro” results may differ significantly from conditions “in vivo”, particularly in man. In vitro results are suggestions, not proofs for processes in real life.”
A group of 15 patients who received CBD over a period ranging from one month to one year were surveyed to gather various data. The researchers sought information about the patient and the caregiver, changes observed in the seizures, neuropsychological effects, side effects and the family’s overall perception following the use of cannabidiol. This simple observational study identified some very encouraging findings:

While overstimulation of the CB1 receptor may lead to symptoms such as high blood pressure and abnormally high cholesterol levels, CBD is a CB1 antagonist, so it is not likely to cause such issues. Furthermore, the World Health Organization has recently issued a global report on CBD, claiming that it has a good safety profile and minimal adverse public health effects.
Gloss and Vickrey conducted a Cochrane systematic review of the use of CBD in the treatment of epilepsy (11). Their methodology included only those trials that were randomized and controlled and excluded case series, case reports, and expert opinion. They were able to identify only 4 randomized controlled studies reported in the literature, and they included a letter to the editor and an abstract. The total number of subjects enrolled in these studies was 48 (11–14). While only four studies and a letter to the editor were in the actual analysis, the authors included a complete reference listing of all articles reviewed for inclusion.
Aura CBD oil actually comes from a well-known and respected brand based in California, but it has a strong presence in the UK with a London office, and currently ships to residential addresses throughout the United Kingdom. Over the last year or so the brand has taken big steps to cement their presence on the UK CBD market, and is now offering high-potency hemp pastes, CBD edibles, and CBD skincare products in addition to their range of top-class CBD tinctures.
Also, please note that CBD should NOT be misunderstood as a miracle cure — and no reputable CBD seller or manufacturer should ever claim otherwise. Furthermore, if you are using CBD for weight loss purposes, don’t expect it to work if you eat fast food three times a day and your exercise routine consists of struggling to twist the cap off your bottle of beer!
Using rigorous review methodology, Gloss and Vickery conclude that based on the low quality of the reports available, there is insufficient data available to draw any conclusions regarding the efficacy and or long-term safety of CBD in treating epilepsy (11). From the data available, it does appear that daily doses of 200 to 300 mg were safe in this small group of patients for a short period of time (14).
Having 1 organic certification is hard enough. BioBloom possesses 3: the Austrian, Swiss and Hungarian Bio certificate and the British Biodynamic Association one, making it the only Cannabidiol product available in the UK with a triple organic certification. This means that from the moment it was planted in the organic soils of an Austro-Hungarian riverbed to the moment it reaches the bottle, the entire process is supervised and tested certified organic. No machines are allowed in the hemp farms and the entire process of harvesting and drying the cannabis plants is done by hand. This is a remarkable product with a very strong taste (perhaps the strongest of all oils we’ve tried), which in our eyes means it is full of goodness. Visit the BioBloom collection.
×